Lung Cancer Europe shared a post on LinkedIn:
“Immunotherapy for lung cancer – what does your gut have to do with it?
A new study in ESMO Open (March 2026) found that people with greater gut microbiome diversity had better outcomes when treated with dual immunotherapy for advanced NSCLC.
The study suggests the gut microbiome may help explain why some people benefit more from certain immunotherapy combinations than others.
This is research stage, but it points to something important: precision medicine in lung cancer may eventually extend beyond the tumor itself.”
Title: Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced non-small-cell lung cancer
Authors: Y. Katayama, A. Fukuda, R. Inoue, H. Kawachi, R. Sawada, T. Harada, A. Yoshimura, A. Okada, S. Shiotsu, Y. Chihara, Y. Takemura, T. Yamada, N. Nishioka, M. Iwasaku, S. Tokuda, T. Takagi, S. Kumagai, S. Koyama, K. Takayama, T. Yamada
Read The Full Article
Other articles about ESMO on OncoDaily.